Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CCXI
Churchill Capital Corp XI
$10.37
+0.4%
$10.24
$10.07
$11.13
$739.61M1.2221,756 shs620 shs
FibroGen, Inc stock logo
FGEN
FibroGen
$9.77
+8.3%
$9.21
$4.85
$12.60
$39.57M0.7740,794 shs31,125 shs
Hypermarcas stock logo
HYPMY
Hypermarcas
$3.81
-4.0%
$4.48
$3.71
$5.50
$2.68B0.724,938 shs9,555 shs
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$27.93
-16.7%
$27.27
$16.24
$45.30
$5.19B0.352.53 million shs13.60 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CCXI
Churchill Capital Corp XI
+0.72%+0.40%+0.78%+1,031,999,900.00%+1,031,999,900.00%
FibroGen, Inc stock logo
FGEN
FibroGen
0.00%0.00%0.00%0.00%+66.16%
Hypermarcas stock logo
HYPMY
Hypermarcas
+1.12%+2.51%-10.24%-3.45%-18.57%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
+0.42%-3.84%+24.24%+87.58%-3.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CCXI
Churchill Capital Corp XI
$10.37
+0.4%
$10.24
$10.07
$11.13
$739.61M1.2221,756 shs620 shs
FibroGen, Inc stock logo
FGEN
FibroGen
$9.77
+8.3%
$9.21
$4.85
$12.60
$39.57M0.7740,794 shs31,125 shs
Hypermarcas stock logo
HYPMY
Hypermarcas
$3.81
-4.0%
$4.48
$3.71
$5.50
$2.68B0.724,938 shs9,555 shs
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$27.93
-16.7%
$27.27
$16.24
$45.30
$5.19B0.352.53 million shs13.60 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CCXI
Churchill Capital Corp XI
+0.72%+0.40%+0.78%+1,031,999,900.00%+1,031,999,900.00%
FibroGen, Inc stock logo
FGEN
FibroGen
0.00%0.00%0.00%0.00%+66.16%
Hypermarcas stock logo
HYPMY
Hypermarcas
+1.12%+2.51%-10.24%-3.45%-18.57%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
+0.42%-3.84%+24.24%+87.58%-3.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CCXI
Churchill Capital Corp XI
1.00
SellN/AN/A
FibroGen, Inc stock logo
FGEN
FibroGen
2.00
Hold$43.00340.12% Upside
Hypermarcas stock logo
HYPMY
Hypermarcas
3.00
BuyN/AN/A
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2.67
Moderate Buy$60.23115.65% Upside

Current Analyst Ratings Breakdown

Latest FGEN, CCXI, LEGN, and HYPMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2026
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
DowngradeSell (D-)Sell (E+)
6/3/2026
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Boost Price TargetBuy$31.00 ➝ $49.00
6/3/2026
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Boost Price TargetBuy$50.00 ➝ $65.00
6/1/2026
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Boost Price TargetBuy$31.00 ➝ $50.00
5/27/2026
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Reiterated RatingBuy
5/20/2026
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
UpgradeSell (E+)Sell (D-)
5/18/2026
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Reiterated RatingBuy$50.00
5/13/2026
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Boost Price TargetOutperform$62.00 ➝ $64.00
5/13/2026
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Boost Price TargetHold$29.00
5/13/2026
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Lower Price TargetOverweight$49.00 ➝ $48.00
5/6/2026
CCXI
Churchill Capital Corp XI
Initiated CoverageSell (E)
(Data available from 6/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CCXI
Churchill Capital Corp XI
$37.20M19.88N/AN/AN/A
FibroGen, Inc stock logo
FGEN
FibroGen
$29.62M1.34N/AN/A($50.89) per share-0.19
Hypermarcas stock logo
HYPMY
Hypermarcas
$1.38B1.95$0.45 per share8.55$3.54 per share1.08
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$1.03B5.04N/AN/A$5.43 per share5.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CCXI
Churchill Capital Corp XI
N/A-$1.89N/AN/AN/AN/AN/AN/AN/A
FibroGen, Inc stock logo
FGEN
FibroGen
-$47.58M$53.480.18N/AN/A2,598.55%N/A-26.27%N/A
Hypermarcas stock logo
HYPMY
Hypermarcas
$213.10M$0.487.945.60N/A19.41%14.08%6.91%8/5/2026 (Estimated)
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-$296.80M-$0.68N/A15.43N/A-21.98%-24.92%-14.87%8/10/2026 (Estimated)

Latest FGEN, CCXI, LEGN, and HYPMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-$0.02-$0.03-$0.01-$0.30$306.51 million$305.10 million
4/29/2026Q1 2026
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A$0.10N/A$0.10N/A$383.13 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CCXI
Churchill Capital Corp XI
N/AN/AN/AN/AN/A
FibroGen, Inc stock logo
FGEN
FibroGen
N/AN/AN/AN/AN/A
Hypermarcas stock logo
HYPMY
Hypermarcas
$0.133.41%N/A27.08%N/A
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CCXI
Churchill Capital Corp XI
N/AN/AN/A
FibroGen, Inc stock logo
FGEN
FibroGen
N/A
3.71
3.60
Hypermarcas stock logo
HYPMY
Hypermarcas
0.61
1.27
0.84
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
N/A
2.13
2.05

Institutional Ownership

CompanyInstitutional Ownership
CCXI
Churchill Capital Corp XI
81.09%
FibroGen, Inc stock logo
FGEN
FibroGen
72.71%
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
70.89%

Insider Ownership

CompanyInsider Ownership
CCXI
Churchill Capital Corp XI
8.30%
FibroGen, Inc stock logo
FGEN
FibroGen
3.07%
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
0.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
CCXI
Churchill Capital Corp XI
N/A71.36 millionN/AN/A
FibroGen, Inc stock logo
FGEN
FibroGen
5704.05 million3.92 millionOptionable
Hypermarcas stock logo
HYPMY
Hypermarcas
10,481704.01 millionN/ANot Optionable
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2,965185.74 million185.70 millionOptionable

Recent News About These Companies

Legend Biotech Corporation Announces Pricing of Public Offering
Legend Biotech Corporation Announces Proposed Public Offering
Barclays Remains a Buy on Legend Biotech (LEGN)
Oppenheimer Remains a Buy on Legend Biotech (LEGN)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Churchill Capital Corp XI NASDAQ:CCXI

$10.36 +0.05 (+0.44%)
Closing price 02:49 PM Eastern
Extended Trading
$10.28 -0.08 (-0.77%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Churchill Capital Corp XI is a blank check company.

FibroGen stock logo

FibroGen NASDAQ:FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Hypermarcas stock logo

Hypermarcas OTCMKTS:HYPMY

$3.81 -0.16 (-4.03%)
As of 03:58 PM Eastern

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

Legend Biotech stock logo

Legend Biotech NASDAQ:LEGN

$27.93 -5.59 (-16.68%)
Closing price 04:00 PM Eastern
Extended Trading
$28.21 +0.28 (+1.00%)
As of 05:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.